TY - JOUR
T1 - Colon cancer, version 3.2014
AU - Benson, Al B.
AU - Venook, Alan P.
AU - Bekaii-Saab, Tanios
AU - Chan, Emily
AU - Chen, Yi Jen
AU - Cooper, Harry S.
AU - Engstrom, Paul F.
AU - Enzinger, Peter C.
AU - Fenton, Moon J.
AU - Fuchs, Charles S.
AU - Grem, Jean L.
AU - Hunt, Steven
AU - Kamel, Ahmed
AU - Leong, Lucille A.
AU - Lin, Edward
AU - Messersmith, Wells
AU - Mulcahy, Mary F.
AU - Murphy, James D.
AU - Nurkin, Steven
AU - Rohren, Eric
AU - Ryan, David P.
AU - Saltz, Leonard
AU - Sharma, Sunil
AU - Shibata, David
AU - Skibber, John M.
AU - Sofocleous, Constantinos T.
AU - Stoffel, Elena M.
AU - Stotsky-Himelfarb, Eden
AU - Willett, Christopher G.
AU - Gregory, Kristina M.
AU - Freedman-Cass, Deborah A.
PY - 2014/7/1
Y1 - 2014/7/1
N2 - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.
AB - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.
UR - http://www.scopus.com/inward/record.url?scp=84903980978&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2014.0099
DO - 10.6004/jnccn.2014.0099
M3 - Article
C2 - 24994923
AN - SCOPUS:84903980978
SN - 1540-1405
VL - 12
SP - 1028
EP - 1059
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 7
ER -